OCT4/SOX2-independent *Nanog* autorepression modulates heterogeneous *Nanog* gene expression in mouse ES cells

Pablo Navarro^{1,*}, Nicola Festuccia¹,
Douglas Colby¹, Alessia Gagliardi¹,
Nicholas P Mullin¹, Wensheng Zhang^{1,3},
Violetta Karwacki-Neisius¹,
Rodrigo Osorno¹, David Kelly²,
Morag Robertson^{1,4} and Ian Chambers^{1,*}

¹MRC Centre for Regenerative Medicine, Institute for Stem Cell Research, School of Biological Sciences, University of Edinburgh, Edinburgh, Scotland and ²Centre Optical Instrumentation Laboratory, Wellcome Trust Centre for Cell Biology, School of Biological Sciences, University of Edinburgh, Edinburgh, Scotland

NANOG, OCT4 and SOX2 form the core network of transcription factors supporting embryonic stem (ES) cell self-renewal. While OCT4 and SOX2 expression is relatively uniform, ES cells fluctuate between states of high NANOG expression possessing high self-renewal efficiency, and low NANOG expression exhibiting increased differentiation propensity. NANOG, OCT4 and SOX2 are currently considered to activate transcription of each of the three genes, an architecture that cannot readily account for NANOG heterogeneity. Here, we examine the architecture of the *Nanog*-centred network using inducible NANOG gain- and loss-of-function approaches. Rather than activating itself, *Nanog* activity is autorepressive and OCT4/SOX2-independent. Moreover, the influence of *Nanog* on *Oct4* and *Sox2* expression is minimal. Using *Nanog*:GFP reporters, we show that *Nanog* autorepression is a major regulator of *Nanog* transcription switching. We conclude that the architecture of the pluripotency gene regulatory network encodes the capacity to generate reversible states of *Nanog* transcription via a *Nanog*-centred autorepressive loop. Therefore, cellular variability in self-renewal efficiency is an emergent property of the pluripotency gene regulatory network.

The EMBO Journal (2012) 31, 4547–4562. doi:10.1038/emboj.2012.321; Published online 23 November 2012

Subject Categories: chromatin & transcription; development

Keywords: heterogeneity; nanog; network; pluripotency; self-renewal

Introduction

For stem cell populations to remain effective, they must balance manifestation of their two defining properties: self-renewal and differentiation (Silva and Smith, 2008). This is achieved by non-genetic heterogeneity, a prominent topic at the forefront of stem cell research (Huang, 2009). Indeed, heterogeneous gene expression is a recurrent property of stem cells that underpins their developmental potency and plasticity (Graf and Stadtfeld, 2008; Martinez-Arias and Brickman, 2009). This has made stem cells a useful model system to study how heterogeneity in gene expression is generated and used by individual cells to undertake decision-making processes (Balazsi *et al.*, 2011).

A paradigmatic example is provided by embryonic stem (ES) cell populations, where a subset of the cells do not express NANOG, the master regulator of the efficiency of self-renewal (Chambers *et al.*, 2003, 2007; Mitsui *et al.*, 2003; Singh *et al.*, 2007; Kalmar *et al.*, 2009). Consequently, NANOG-negative ES cells possess an increased differentiation propensity compared with the highly self-renewing NANOG-positive subpopulation, in which high NANOG levels shield cells from commitment signals (Chambers *et al.*, 2003, 2007). Moreover, NANOG expression is mosaic in the inner cell mass of the blastocyst from which ES cells are derived (Chazaud *et al.*, 2006; Dietrich and Hiiragi, 2007; Plusa *et al.*, 2008; Nichols and Smith, 2011). While NANOG-positive cells are the founders of the epiblast from which the embryo proper originates, NANOG-negative cells give rise to the primitive endoderm, which contributes to extra-embryonic tissues. Therefore, heterogeneous NANOG expression enables important fate decisions and its relevance is illustrated by the observation that elimination of NANOG heterogeneity is associated with a failure to undergo normal embryogenesis and with a considerable resistance of ES cells to differentiate (Chambers *et al.*, 2003, 2007; Nichols *et al.*, 2009).

The mechanisms associated with heterogeneous NANOG expression are largely unknown and ill-defined. However, it is known that NANOG heterogeneity is governed by transcriptional switching of *Nanog* (Chambers *et al.*, 2007; Kalmar *et al.*, 2009). Thus, instead of acting as a static regulatory platform continuously preserving the undifferentiated state, the gene regulatory network supporting self-renewal is dynamic, intermittently silencing *Nanog* to provide temporal opportunities for differentiation. When this study was initiated, the view of the network proposed that *Nanog* and other regulators form a stable, self-sustaining circuitry consisting of positive autoregulatory and feed-forward loops (Jaenisch and Young, 2008). In particular, NANOG was believed to activate transcription of *Oct4* and *Sox2*, two additional pluripotency factors, which in turn activate themselves, each other and *Nanog* (Figure 1A). Although this architecture appears intuitively

*Corresponding authors. P Navarro or I Chambers, MRC Centre for Regenerative Medicine, Institute for Stem Cell Research, University of Edinburgh, School of Biological Sciences, 5 Little France Drive, Edinburgh EH16 4UU, Scotland. Tel: +44 131 651 9500; Fax: +44 131 651 9501; E-mail: pablo.navarro@ed.ac.uk or ichambers@ed.ac.uk

³Present address: Wellcome Trust Sanger Institute, Hinxton CB10 1HH, England

⁴Present address: MRC Human Genetics Unit, University of Edinburgh, Crewe Road, Edinburgh EH4 2XU, Scotland

Received: 19 July 2012; accepted: 9 November 2012; published online: 23 November 2012

Figure 1 Negative correlation between NANOG protein levels and transcription activity of the *Nanog* locus. **(A)** Architecture of the core pluripotency network inferred from genome-wide analyses (Jaenisch and Young, 2008). **(B)** Schematic diagram of WT E14Tg2a, NANOG overexpressing EF4 and *Nanog*^{-/-} RCNβH-B(t) cells. Note the presence of *Nanog* intron 1 sequences at the endogenous *Nanog* locus of all lines: this is the region where the RT-(Q)PCR primers (black dots within the E14Tg2a diagram) and the RNA-FISH probe (black line within the E14Tg2a diagram) were designed and used to detect the activity of the *Nanog* locus. A full description of these cell lines can be found in previous publications (Chambers *et al*, 2003, 2007). Tg, transgene. **(C)** Analysis of the level of NANOG protein, *Nanog* mRNA and *Nanog*-derived pre-mRNA (E14Tg2a RNA levels set to 1) in EF4, E14Tg2a and RCNβH-B(t) ES cells (*n* = 2; error bars represent s.e.m.). **(D)** Co-transfection of either a luciferase reporter driven by a 6-kb-long *Nanog* promoter (left), or by a *Rex1* promoter (right panel) in supertransfectable E14/T ES cells (Chambers *et al*, 2003) with either an empty vector (EV, set to 1), a NANOG-expressing vector (NANOG) or a vector expressing a mutant form of NANOG unable to bind DNA (NANOG:N51-A). *n* = 2; error bars represent s.e.m.

advantageous for the efficient maintenance and exit from pluripotency, it predicts the emergence of coherent expression patterns of OCT4, SOX2 and NANOG. However,

fluctuating *Nanog* transcription occur within cells expressing relatively uniform levels of OCT4/SOX2 (Chambers *et al*, 2007).

Figure 2 Endogenous *Nanog* transcription is rapidly upregulated upon loss of exogenous NANOG expression. (A) Schematic diagram of Tamoxifen-inducible *Nanog*-null ES cells. In addition to the different features shown, RCNβH ES cells carry a Cre-ER¹² transgene knocked-in to *Rosa26*. (B) FACS profiles monitoring the deletion of the *Nanog* cDNA transgene after 12, 24 and 48 h of Tamoxifen treatment. (C) Analysis of NANOG protein (top), *Nanog* mRNA (middle), and *Nanog* pre-mRNA expression (bottom) in RCNβH cells treated with Tamoxifen for 0 (set to 1 for the RT-(Q)PCR), 12, 24 and 48 h (n = 2; error bars represent s.e.m.). (D) Western blot analysis of OCT4 and SOX2 at the same time points of Tamoxifen treatment. (E) Relative expression of *Oct4*, *Sox2*, *Esrrb* and *Klf4* transcripts after 48 h of Tamoxifen treatment (untreated cells set to 1; n = 7; error bars represent s.e.m.).

As autoregulation is widely associated with the dynamic behaviour of regulatory networks (Balazsi *et al*, 2011), we aimed to examine the details of *Nanog* autoregulation. To do so, we used a genetic approach consisting of inducible systems of gain- and loss-of-function combined with *Nanog*:GFP reporters. In agreement with a recent report (Fidalgo *et al*, 2012), we establish that the current architecture of the core pluripotency network must be overturned: *Nanog* activity is autorepressive. Moreover, we report that the NANOG-mediated control of *Oct4*/*Sox2* expression is minimal. We further show that the autorepressive mechanism does not involve OCT4/SOX2 and, importantly, that *Nanog* autorepression controls switching of *Nanog* transcription to modulate *Nanog* gene expression heterogeneity.

Results

NANOG negatively influences *Nanog* transcription

In several regulatory networks associated with fluctuating gene expression, one or more of the components are negatively autoregulated, either directly or indirectly (Balazsi *et al*, 2011). However, in the case of the pluripotency gene regulatory network, NANOG is considered to act as a transcriptional activator of *Nanog* gene expression (Figure 1A; Jaenisch and Young, 2008). To experimentally

test the validity of this idea, we used quantitative RT-PCR (RT-(Q)PCR) to determine the level of pre-messenger RNA produced by the *Nanog* locus in cell lines expressing differing levels of NANOG (Figure 1B and C). We used five primer pairs located within a region of *Nanog* intron 1 that remains intact in *Nanog*-null ES cells to assess the transcriptional activity of the *Nanog* locus in wild-type (WT) ES cells (E14Tg2a), *Nanog*-null ES cells (RCNβH-B(t)) and in cells overexpressing NANOG from a randomly integrated cDNA transgene (EF4). In contrast to the accepted model, we found a negative correlation between the level of *Nanog* mRNA and protein (derived from the endogenous alleles in E14Tg2a and from both the endogenous alleles and the transgene in EF4) and the level of transcription of the endogenous *Nanog* locus (Figure 1C). This may suggest that NANOG negatively affects transcription of the *Nanog* gene. In agreement, we found that a luciferase gene driven by a 6-kb-long *Nanog* promoter region is repressed by co-transfecting a vector expressing WT NANOG but not a variant in which the DNA-binding homeodomain carries a point mutation known to abolish binding of homeodomain proteins to DNA (Pomerantz and Sharp, 1994; NANOG:N51-A, Figure 1D). Conversely, a *Rex1* promoter-driven luciferase gene was shown to be *trans*-activated by NANOG (Figure 1D), confirming that NANOG can both activate or

repress transcription from distinct pluripotency-associated promoters.

The inducible loss of NANOG leads to increased Nanog transcription

To address whether the upregulation of *Nanog* transcription is a primary response to the loss of NANOG, we first analysed the dynamics of pre-messenger transcription from the endogenous *Nanog* locus in inducible *Nanog*-null cells by using RCN β H cells, the parental line from which RCN β H-B(t) cells were derived (Chambers *et al*, 2007). RCN β H cells are *Nanog*-null cells that express *Nanog* mRNA from a constitutive transgene from which the *Nanog* ORF can be deleted by Tamoxifen treatment. Upon deletion of the *Nanog* transgene, GFP is brought under the control of the constitutive CAG promoter (Figure 2A).

After 12 h of Tamoxifen treatment, around 75% of the cells have undergone the deletion of the *Nanog* transgene as evaluated by FACS analysis (Figure 2B). However, exogenous *Nanog* mRNA and protein is only reduced by half and this is accompanied by a modest upregulation of endogenous *Nanog* locus transcription (Figure 2C). After 48 h of treatment, when 98% of the cells are GFP-positive (Figure 2B) and exogenous NANOG protein and mRNA become essentially undetectable (Figure 2C), the production of pre-mRNA from the endogenous *Nanog* locus has increased three-fold (Figure 2C). Importantly, OCT4 and SOX2 protein (Figure 2D) and mRNA (Figure 2E) remained expressed following loss of exogenous NANOG expression, suggesting efficient maintenance of the undifferentiated state. However, other pluripotency genes such as *Klf4* and *Esrrb* were downregulated after 48 h of Tamoxifen treatment (Figure 2E).

The inducible restoration of NANOG leads to reduced Nanog transcription

In a complementary approach, we introduced a transgene encoding a NANOG-ER^{T2} fusion protein to an independent *Nanog*-null ES cell line (T β C44Cre6; Chambers *et al*, 2007) in order to restore nuclear NANOG expression upon Tamoxifen treatment (44NERT; Figure 3A). Three independent clones were generated, two expressing *Nanog* transcripts at similar levels to WT ES cells (44NERTc1&2) and one in which *Nanog* transcripts are increased (44NERTc3; Figure 3B). However, immunoblot analyses indicated that in the three clones, and in particular in 44NERTc3, NANOG-ER^{T2} is overexpressed as compared with the level of WT NANOG detected in E14Tg2a cells (Figure 3C). The nuclear translocation of NANOG-ER^{T2} triggered by Tamoxifen (Figure 3D) leads to an accompanying reduction of endogenous *Nanog* pre-mRNA expression to ~50% of starting levels by 6 h (Figure 3E), in cells that display unchanged levels of OCT4 and SOX2 (Figure 3F). After 24 h of Tamoxifen treatment, endogenous *Nanog* downregulation is maintained while OCT4 and SOX2 mRNA and protein levels remain unaffected (Figure 3G and H). In contrast, increased levels of *Esrrb* and *Klf4* mRNA (Figure 3G) and pre-mRNA (Figure 3I) were detected upon Tamoxifen treatment, mirroring the results observed in RCN β H cells.

Our results show that the *Nanog* gene responds rapidly to the inducible depletion and restoration of NANOG. Whether this effect is a direct consequence of NANOG activity was

investigated by treating 44NERT cells with Tamoxifen and Cycloheximide, a potent inhibitor of protein synthesis. Compared with cells treated with Cycloheximide alone, cells treated with Tamoxifen and Cycloheximide for 2.5 h displayed a 25% (clone#1), 18% (clone#2) and 35% (clone#3) downregulation of endogenous *Nanog* pre-mRNA (Figure 3J). Thus, the effect of NANOG is independent of any additional putative repressor of *Nanog*, whose expression may be activated by NANOG.

NANOG represses Nanog through unknown binding sites

Our results contrast markedly with the generally accepted model of *Nanog* autoregulation, and in particular with a previous report showing that a putative NANOG-binding site located 5-kb upstream of the *Nanog* transcription start site conferred high transcriptional activity to a luciferase gene driven by the minimal *Oct4* promoter (Wu *et al*, 2006). To investigate this discrepancy, we established a luciferase strategy in 44NERTc3 cells, in which transfection of the 6-kb-long *Nanog* promoter/luciferase construct (Long Pr. construct, Figure 3K) recapitulates the NANOG-mediated repression of *Nanog*-driven transcription upon Tamoxifen treatment (Figure 3L). We then generated a chimaeric reporter in which the –5 kb region was positioned adjacent to the minimal *Nanog* promoter instead of the *Oct4* promoter used by Wu *et al* (WT-Enh & Min Pr. Figure 3K). We found that Tamoxifen treatment of 44NERTc3 cells transfected with this DNA recapitulated the ~50% reduction in luciferase activity observed with the Long Pr. construct (Figure 3M). Next, we introduced the same deletion of the putative NANOG-binding site previously assessed (Mut-Enh & Min Pr., Figure 3K; Wu *et al*, 2006). When this reporter was transfected into 44NERTc3 cells, reduced luciferase activity was observed compared with the WT-Enh & Min. Pr reporter (Figure 3M), as previously shown (Wu *et al*, 2006). However, this decrease was observed in cells that were not treated with Tamoxifen (i.e., in the absence of nuclear NANOG), indicating that the reduced activity conferred by this mutation is not due to a lack of NANOG binding as speculated previously. Moreover, addition of Tamoxifen reduced the activity of the mutant construct by around 50%, similar to the reduction observed with the WT-Enh & Min Pr. (Figure 3M). We conclude from this that the previously identified putative NANOG-binding site is not responsible for NANOG-mediated regulation of *Nanog*. While it is also clear that an as yet unknown transcriptional activator binds to the deleted region, our results indicate strongly that *Nanog* is subject to direct autorepression through NANOG binding to unknown sites within the –5 kb region.

Dose response of NANOG-mediated repression of Nanog

After 3 and 6 h of Tamoxifen treatment, *Nanog* pre-mRNA is slightly more downregulated in 44NERTc3 cells than in the other two clones (Figure 3E). Similarly, FACS analyses of GFP expression, which in 44NERT cells is expressed from one of the endogenous *Nanog* alleles (Figure 3A), confirmed both that endogenous *Nanog* gene activity is reduced upon Tamoxifen treatment and that this reduction is more prominent in 44NERTc3 than in 44NERTc1 and c2 cells (Figure 4A). This was particularly obvious when the relative *Nanog*:GFP

Figure 3 Endogenous *Nanog* transcription is rapidly downregulated upon restoration of nuclear NANOG expression. (A) Schematic diagram of Tamoxifen-inducible 44NERT cells. (B) Relative expression of *Nanog* mRNA in WT E14Tg2a cells, *Nanog*-null TgC44Cre6 (a schematic picture of this line is shown in Figure 7C), and three independent 44NERT clones ($n = 3$; error bars represent s.e.m.). (C) Immunoblot analysis of NANOG expression in 44NERT and WT E14Tg2a ES cells (n.s. designates a non-specific band). (D) Immunofluorescence detection of NANOG (red) and the RNAPII (green) in 44NERTc3 cells before (left) and after 30 min of Tamoxifen treatment (right), on DAPI-stained nuclei (blue). (E) Relative quantification of endogenous *Nanog*-driven pre-mRNA after 0 (set to 1 for each clone), 3 and 6 h of Tamoxifen treatment in three independent 44NERT clones ($n = 2$; error bars represent s.e.m.). (F) Immunoblot analysis of OCT4 and SOX2 after 3 and 6 h of Tamoxifen treatment of 44NERTc3 cells. (G) Relative expression of *Nanog* pre-mRNA, and of four pluripotency transcripts (*Oct4*, *Sox2*, *Esrrb* and *Klf4*) after 24 h of Tamoxifen treatment ($n = 6$; error bars represent s.e.m.). (H) Immunoblot analysis of OCT4 and SOX2 in untreated and 24 h-treated 44NERT clones. (I) Relative quantification of *Esrrb* and *Klf4* pre-mRNA production after 3 h of Tamoxifen treatment in the three 44NERT clones. (J) Relative quantification of *Nanog* locus pre-mRNA in the three 44NERT clones treated for 2.5 h with either Cycloheximide (Chx, set to 1 for each clone and shown as a single bar; Control), or Cycloheximide plus Tamoxifen ($n = 2$; error bars represent s.e.m.). (K) Schematic representation of the three luciferase reporter constructs used in this study. (L) Relative luciferase activity of 44NERTc3 cells transfected with the Long Pr. construct and treated for 24 h with Tamoxifen (untreated cells set to 1; $n = 2$; error bars represent s.e.m.). (M) Relative luciferase activity of 44NERTc3 cells transfected with either the WT-Enh & Min Pr. or the Mut-Enh & Min Pr. constructs and treated for 24 h with Tamoxifen (untreated cells transfected with the WT construct were set to 1; $n = 2$; error bars represent s.e.m.).

population median was calculated (Figure 4B). Given that 44NERTc3 expresses the highest levels of NANOG-ERT² among the three 44NERT clones (Figure 3C), this suggests that the NANOG-mediated repression of *Nanog* might be dose responsive.

To more rigorously assess the dose-responsiveness of the NANOG-mediated repression of *Nanog*, in particular at low cellular doses, we used an independent genetic system of NANOG restoration (44iN cells; Festuccia *et al*, 2012). Like

44NERT cells, 44iN were derived from TgC44Cre6 cells and therefore express the GFP from one *Nanog* allele. Moreover, a WT version of NANOG can be expressed upon addition of Doxycycline to 44iN cultures (Figure 4C). Treatment of 44iN cells with increasing concentrations of Doxycycline leads to a progressive increase of exogenous *Nanog* mRNA expression (Figure 4D). Immunoblot analyses (Figure 4E) showed that among the tested conditions, two were associated with levels of NANOG clearly below WT levels (15 and 30 ng/ml of

Figure 4 Dose responsiveness of NANOG-mediated repression of *Nanog*. (A) FACS profiles of the three 44NERT clones before (blue) and after 48 h of Tamoxifen treatment (red). (B) Relative *Nanog*:GFP population median in untreated (blue, set to 1 for each clone and shown as a single bar; Control) and Tamoxifen-treated 44NERT clones ($n = 2$; error bars represent s.e.m.). (C) Schematic diagram of Doxycycline-inducible 44iN cells. (D) Relative *Nanog* mRNA expression measured in 44iN cells treated for 48 h with the indicated concentrations of Doxycycline (3000 ng/ml set to 1; $n = 3$; error bars represent s.e.m.). (E) Immunoblot analysis of NANOG expression in WT E14Tg2a and in 44iN cells treated for 48 h with the indicated concentrations of Doxycycline. (F) FACS profiles of untreated and Doxycycline-treated 44iN cells (48 h at the indicated doses). (G) Relative *Nanog*:GFP population median in untreated (blue, set to 1) and Doxycycline-treated 44iN cells (48 h at the indicated doses; untreated cells set to 1; $n = 3$; error bars represent s.e.m.). (H) Luciferase activity driven by a 6-kb-long *Nanog* promoter transcribed in 44iN cells and treated with different doses of Doxycycline for 24 h (untreated cells set to 1; $n = 2$; error bars represent s.e.m.).

Doxycycline), whereas three other conditions produced elevated levels of NANOG expression (100, 300 and 3000 ng/ml of Doxycycline).

Analysis of the FACS profiles showed that at all concentrations of Doxycycline, *Nanog*:GFP is downregulated as compared with untreated 44iN cells (Figure 4F). Interestingly, when the *Nanog*:GFP population median was plotted, a gradual and progressive downregulation of *Nanog*:GFP expression was observed (Figure 4G), starting from the lowest concentration of Doxycycline which is associated with very low levels of exogenous NANOG (Figure 4D and E). Moreover, when untreated 44iN cells were transfected with the 6-kb-long *Nanog* promoter/luciferase construct and cultivated for 24 h in the same range of Doxycycline concentrations, a gradual reduction in luciferase activity was observed with increasing doses of Doxycycline (Figure 4H).

We conclude that even at low concentrations, NANOG represses endogenous *Nanog* transcription in a clear dose-response manner.

Transcriptional foundation of *Nanog* autorepression

The results presented above, in which pre-mRNA production by the *Nanog* locus responds rapidly to the loss and restoration of NANOG function (Figures 2–4), suggest that transcriptional mechanisms underlie NANOG-mediated repression of *Nanog*. In line with the idea of direct and transcriptional *Nanog* autorepression, chromatin immunoprecipitation (ChIP) analyses have shown that NANOG binds at the *Nanog* locus. Indeed, it is clear from genome-wide studies that two hotspots of transcription factor binding control *Nanog* transcription in ES cells: the promoter and a 5-kb upstream region where NANOG binding occurs (Loh *et al*,

Figure 5 Transcriptional foundation of *Nanog* autorepression. (A) (Top) Schematic representation of the 5' end of the *Nanog* locus analysed by ChIP. Each vertical bar represents a primer pair. The five primer pairs coloured in red are located within *Nanog* intron 1 and were used to detect pre-mRNA transcription from the endogenous locus (also represented in Figure 1B). The arrow represents the transcription start site (TSS) of *Nanog*, and the grey box *Nanog* exon 1. (Bottom) ChIP profile obtained in E14Tg2a using an irrelevant IgG as a negative control ($n = 2$). (B–D) ChIP analysis of NANOG across the *Nanog* 5' region in the indicated lines and conditions (B, E14Tg2a, $n = 4$; C, RCNβH, $n = 6$; D, 44NERT, $n = 6$). (E) Tamoxifen-induced changes in binding of the indicated factors at the *Nanog* promoter as determined by ChIP in RCNβH (48 h of Tamoxifen treatment) and 44NERT (24 h of Tamoxifen treatment). Error bars represent s.e.m.

2006; Chen *et al*, 2008; Marson *et al*, 2008; Kim *et al*, 2008). Using ChIP with 22 primer pairs covering 9 kb of the *Nanog* locus from -6 kb to $+3$ kb relative to the transcription start site (Figure 5A), we observed maximal binding of NANOG at the -5 kb region (Figure 5B). Importantly, NANOG binding is appropriately abolished (Figure 5C) and restored (Figure 5D) upon Tamoxifen treatment of RCNβH and 44NERT ES cells, respectively.

To firmly establish the transcriptional foundation of *Nanog* autorepression, we monitored the modifications occurring at the *Nanog* promoter upon loss and restoration of NANOG function. The loss of NANOG binding at *Nanog* in RCNβH cells was associated with increased recruitment of the transcriptional machinery to the *Nanog* promoter, including the general transcription factor TFIIB, the RNA Polymerase II and its Ser5-phosphorylated form (Figure 5E). This was accompanied by increased enrichment of histone marks widely associated with euchromatin and gene activation such as trimethylation of H3K4 and acetylation of H3K9 (Figure 5E). Conversely, restoring nuclear NANOG to 44NERT cells leads to the exact opposite consequences (Figure 5E). Altogether, our results suggest that NANOG acts as a direct transcriptional repressor of *Nanog* gene transcription.

OCT4 triggers SOX2 binding at *Nanog* and activates *Nanog* transcription

As our results established that NANOG represses itself, a result which is contrary to the generally accepted model of *Nanog* regulation by pluripotency transcription factors, we probed OCT4-mediated control of *Nanog*. Using ChIP, we found that OCT4 (Figure 6A) and its interacting partner SOX2 (Figure 6B), bind at the -5 kb and promoter regions of *Nanog*. In contrast to NANOG, maximal binding of OCT4 and SOX2 was detected at the *Nanog* promoter in the vicinity of the characterised Oct/Sox motif (Kuroda *et al*, 2005; Rodda *et al*, 2005).

We next used ZHBTc4 ES cells in which both *Oct4* alleles are deleted and OCT4 expression is supported by a Doxycycline suppressible transgene (Niwa *et al*, 2000). After 12 h of treatment, OCT4 binding is no longer detectable (Figure 6C). The loss of OCT4 is associated with a lack of SOX2 binding at the *Nanog* promoter (Figure 6D) and to a downregulation of *Nanog* transcription as illustrated by reduced levels of *Nanog* pre-mRNA production and decreased recruitment of the RNAPII and TFIIB at the *Nanog* promoter (Figure 6E). These results confirm previous studies, indicating that OCT4 is required for SOX2 to bind at *Nanog* such that they can together activate transcription from

Figure 6 Mutual independence of *Nanog* autorepression and OCT4/SOX2-mediated activation. (A) ChIP analysis of OCT4 binding at *Nanog* in E14Tg2a ($n = 5$). (B) ChIP analysis of SOX2 binding at *Nanog* in E14Tg2a ($n = 5$). (C, D) ChIP analysis of binding at *Nanog* after 12 h of Doxycycline treatment of ZHBTc4 cells for OCT4 (C, $n = 7$) and SOX2 (D, $n = 8$). (E) Changes in *Nanog* mRNA and pre-mRNA levels ($n = 7$) and binding levels of RNAPII ($n = 3$) and TFIIB ($n = 3$) at the *Nanog* promoter, after 12 h of Doxycycline treatment of ZHBTc4 ES cells (untreated cells set to 1; error bars represent s.e.m.). (F) ChIP analysis of NANOG binding at *Nanog* after 12 h of Doxycycline treatment of ZHBTc4 cells ($n = 6$). (G–J) ChIP analysis of OCT4 and SOX2 in RCNβH ($n = 4$) and 44NERT ($n = 3$) inducible systems. (K) Relative expression of total *Nanog* transcripts in ZHBTc4 ES cells (set to one) and in two derivative lines in which the NANOG-ER^{T2} transgene was randomly integrated (ZNERTc1&2, $n = 2$). (L) Expression of *Nanog* pre-mRNA in untreated ZNERT clones (Ctl, set to 1) and after 12 h of treatment with the indicated molecules ($n = 2$ for each condition, error bars represent s.e.m.).

the *Nanog* promoter (Kuroda *et al*, 2005; Rodda *et al*, 2005; Rahl *et al*, 2010).

***Nanog* autorepression and OCT4/SOX2-mediated activation are independent**

Upon loss of OCT4, there is small decrease in NANOG binding at *Nanog* (Figure 6F) consistent with the slight reduction in *Nanog* expression (Figure 6E). If OCT4 was required for NANOG to bind at the –5 kb region, then we should have observed a more drastic reduction of NANOG binding in Doxycycline-treated ZHBTc4 cells, such as is observed for SOX2 at the *Nanog* promoter (Figure 6D). This therefore indicates that NANOG binding at *Nanog* is independent from OCT4/SOX2. Furthermore, we found that the level of binding of OCT4 and SOX2 to *Nanog* remains essentially unaltered upon loss or restoration of NANOG binding in RCNβH or 44NERT ES cells, respectively (Figure 6G–J). This suggests that the autorepressive activity associated with NANOG does not influence binding of OCT4/SOX2.

Finally, to determine whether NANOG binding to *Nanog* affected OCT4/SOX2 function, we introduced the NANOG-ER^{T2} transgene into ZHBTc4 cells (generating ZNERT cells, Figure 6K). Upon treatment with Doxycycline or Tamoxifen, transcription of the endogenous *Nanog* locus was reduced in independent ZNERT clones (Figure 6L). Notably, repressive activity is increased when ZNERT cells are simultaneously treated with Tamoxifen and Doxycycline (Figure 6L). The ability of NANOG to further repress endogenous *Nanog* transcription, even when binding of OCT4 to *Nanog* is abolished and when binding of SOX2 to *Nanog* is dramatically reduced, strongly supports the notion that *Nanog* autorepression is not mediated by interference with the OCT4/SOX2-dependent activation of *Nanog* transcription.

***NANOG* decreases the probability of *Nanog* transcription**

To assess whether the difference in *Nanog* transcription levels observed upon modulation of NANOG binding at *Nanog* (Figures 1–5) results from partial modulations affecting all the cells in the population or, alternatively, is associated with a variation in the number of cells transcribing *Nanog*, we established an RNA-FISH approach to analyse nascent RNA transcription from the endogenous *Nanog* locus in single cells (Figure 7A). As for the RT-PCR analysis, we took advantage of the region of *Nanog* intron 1 remaining intact in *Nanog*-null cells to design an intronic, 2-kb-long probe that could be used in all our cell lines (Figure 1B). We observed that the proportion of cells transcribing *Nanog* is inversely correlated to NANOG levels (Figure 7B) in cells overexpressing NANOG from a transgene (EF4), WT cells (E14Tg2a) and *Nanog*-null cells (RCNβH-B(t)). Likewise, the loss of exogenous NANOG in RCNβH cells leads to an increase in the proportion of cells transcribing endogenous *Nanog*, whereas this proportion is reduced upon restoration of NANOG in 44NERT (Figure 7B). Thus, the differences in *Nanog* transcription levels that we observed within a population upon alteration of NANOG activity are due to changes in the number of cells actively transcribing *Nanog* and not to a variation in the expression level of cells already transcribing *Nanog*. Interestingly, in populations of cells permanently expressing exogenous NANOG (EF4, Tamoxifen-untreated RCNβH and Tamoxifen-treated 44NERT), *Nanog* is not homogeneously silent.

Conversely, in cells lacking NANOG activity (RCNβH-B(t), Tamoxifen-treated RCNβH and Tamoxifen-untreated 44NERT), *Nanog* is not homogeneously active. This suggests that additional activities contribute to the frequency of *Nanog* transcription in ES cell populations.

We found *Nanog* transcription to be preferentially mono-allelic in ES cells, as recently reported (Miyanari and Torres-Padilla, 2012). However, the relative proportion of mono- and biallelically transcribing cells is unchanged under all our experimental conditions, with around 20% of cells in which transcription can be detected originating from both alleles (Figure 7B). Although using RNA-FISH we cannot exclude that NANOG does not control the dynamic properties of mono/biallelic switching, the maintenance of a similar ratio of mono/biallelically transcribing cells in all our experimental conditions indicates that the variation in *Nanog* pre-mRNA production that we observe upon loss/restoration of NANOG does not result from a major mono/biallelic switch.

***NANOG* maximises *Nanog* transcription heterogeneity**

The RNA-FISH experiments indicate that NANOG reduces the probability of *Nanog* transcription, suggesting that *Nanog* autorepression may contribute to the generation of a heterogeneous expression profile. To further examine the relationship between heterogeneous NANOG expression and *Nanog* transcription, we used the previously described TNG and TβC44Cre6 cell lines, which express GFP from the *Nanog* locus (Chambers *et al*, 2007). Whereas in TNG the remaining *Nanog* allele is WT, in TβC44Cre6 the other *Nanog* allele has been deleted (Figure 7C). We also monitored *Nanog*:GFP expression in 44NERT cells in which nuclear NANOG activity can be experimentally controlled with Tamoxifen (Figure 3A). These three cell lines were plated in parallel, and cultured for 5 days after which expression of GFP and of SSEA-1, a marker of the undifferentiated state, were assessed by FACS (Figure 7D). Overall, no drastic differences in SSEA-1 expression were observed, with the large majority of cells being SSEA-1 positive. However, compared with TNG cells only a small fraction of the TβC44Cre6 and 44NERT cell population was *Nanog*:GFP-negative, as delimited by the analysis of non-GFP ES cells (Figure 7D). Upon Tamoxifen treatment, 44NERT cells gave rise to a significant population of *Nanog*:GFP-negative cells. This indicates that *Nanog* autorepression contributes to the generation of cells in which *Nanog* transcription is silent.

Further analysis of the GFP profile corresponding to the SSEA-1 high subpopulation (Figure 7D) showed clear differences between cells expressing active NANOG (TNG and Tamoxifen-treated 44NERT cells) and those which lack nuclear NANOG (TβC44Cre6 and 44NERT cells). In the absence of functional NANOG expression, the peak of GFP expression is located at a significantly higher level of GFP fluorescence (Figure 7E). Indeed, using the gating strategy outlined in Figure 7F, we found that the highest percentage of cells expressing very high levels of *Nanog*:GFP (VHG; Figure 7F) is observed in cells lacking nuclear NANOG. In response to Tamoxifen treatment, the peak of GFP expression in 44NERT cells is relocated to essentially the same fluorescence value as TNG cells (Figure 7E) and, importantly, there is a clear increase in the proportion of cells expressing no (NG), low (LG) and medium (MG) levels of *Nanog*:GFP (Figure 7F). In particular, the proportion of NG and LG cells increased by more than two-fold upon Tamoxifen treatment (Figure 7F).

Figure 7 NANOG maximises *Nanog:GFP* heterogeneity. (A) Representative RNA-FISH conducted in RCNβH-B(t) with a probe recognising 2 kb of *Nanog* intron I (blue, DAPI; green, *Nanog* RNA-FISH probe). 'm' indicates cells displaying monoallelic transcription and 'b' cells transcribing *Nanog* biallelically. (B) Quantification of RNA-FISH experiments in the indicated lines and conditions. Note that in 44NERT ES cells only the non-GFP allele can be visualised with the intronic probe (Figure 3A). The total number of counted nuclei is as follows: E14Tg2a, 422; EF4, 234; RCNβH-B(t), 385; RCNβH -Tam, 225; RCNβH + Tam, 308, 44NERT -Tam, 115; 44NERT + Tam, 114. (C) Schematic diagram of *Nanog:GFP* reporters retaining a functional *Nanog* locus (TNG) or not (TβC44Cre6) (D) FACS analysis of GFP (x axis) and SSEA-1 (y axis) expression in TNG, TβC44Cre6 and 44NERTc3 cells (treated as indicated with Tamoxifen) cultured in parallel for 5 days in the absence of selection for *Nanog* transcription (red lines). Non-GFP E14Tg2a are shown as controls either unstained (black) or SSEA-1 stained (blue). (E) Histogram representing the level and distribution of GFP expression for the indicated cell lines after gating for high SSEA-1 expression as shown in (D). (F) (Top) Relative position of the gates used to quantify the proportion of cells residing in distinct *Nanog:GFP* compartments, established on the basis of TNG (black histogram) and non-fluorescent ES cells (E14Tg2a, grey histogram). NG, negative; LG, low GFP; MG, medium GFP; HG, high GFP; VH, very high GFP. (Bottom) Averaged proportion of cells expressing different levels of GFP in each of the indicated cell lines ($n=3$, error bars represent s.e.m.).

NANOG is a major regulator of *Nanog*-state transitions

To determine the role of NANOG in the transitions between high and low *Nanog:GFP* expression, we used a FACS-sorting strategy in which we isolated 44NERT cells that were cultured

in the absence of Tamoxifen and which expressed either very high levels of *Nanog:GFP* (VH) or none at all (NG; Figure 7F). Following FACS-sorting, the cells were replated in either the presence or absence of Tamoxifen and cultured

Figure 8 NANOG is a major regulator of transcriptional switching of *Nanog*. (A) Histograms representing the level and distribution of GFP after sorting 44NERTc3 cells expressing VH levels (top) and NG levels (bottom) of *Nanog*:GFP and replating them in parallel for 3, 5, 10 and 20 days either in the absence (blue) or the presence (red) of Tamoxifen. (B) Representative pictures of 44NERTc3 cells cultured for 20 days in the presence or absence of Tamoxifen (+ / - TAM), after sorting VH and NG subpopulations.

in parallel for 20 days. We used FACS analyses to determine the profiles of *Nanog*:GFP expression at 3, 5, 10 and 20 days post-sorting (Figure 8A). We found that in the presence of Tamoxifen, sorted VH 44NERT cells transit faster and more efficiently to the *Nanog*:GFP-negative compartment than in the absence of Tamoxifen. Conversely, sorted NG 44NERT cells re-express *Nanog*:GFP efficiently only in the absence of Tamoxifen. We conclude that NANOG promotes the transition to and blocks the exit from the *Nanog*-inactive state.

Following sorting of VH/NG 44NERT cells, differentiation was observed exclusively in the absence of Tamoxifen (Figure 8B). Therefore, a fraction of the cells expressing reduced levels of *Nanog*:GFP in the absence of Tamoxifen are likely to correspond to the differentiation events typical of prolonged culture of *Nanog*-null cells in the absence of drug selection for expression of the endogenous loci (Chambers *et al*, 2007). This reinforces the major differences that we observe in the efficiency with which cells leave one of the extreme *Nanog*:GFP states and enter the other upon modulation of nuclear NANOG activity (Figure 8A). We conclude that *Nanog* autorepression promotes the transition to and the maintenance of the transcriptionally silent state of *Nanog*, thereby controlling the efficiency of transcriptional switching and the dynamics associated with heterogeneous NANOG expression.

Nanog autorepression is operational in serum-free '2i + LIF' conditions

Conventional culture of ES cells uses serum and LIF-containing medium. Recently however, supplementation of serum-free medium with LIF and inhibitors of MEK and GSK3 has

been shown to enable maintenance of ES cell self-renewal (Ying *et al*, 2008). Under this so-called '2i + LIF' conditions, spontaneous differentiation of ES cells is abrogated and this correlates with homogeneous NANOG expression throughout the ES cell culture (Wray *et al*, 2010; Marks *et al*, 2012). In agreement, we found that TNG cells cultured in '2i + LIF' are morphologically undifferentiated and exhibit homogenous *Nanog*:GFP expression (Figure 9A and B).

Contrary to our expectations, we found that *Nanog*-null/GFP cells (T β C44Cre6) exhibit considerable levels of differentiation when grown in '2i + LIF', as observed by morphology and by the accumulation of cells expressing low *Nanog*:GFP (Figure 9A and B). This suggests that NANOG is required to allow MEK/GSK3 inhibition to fully exert its pro-self-renewal effect. Despite their higher propensity to differentiate, we found that undifferentiated T β C44Cre6 colonies produced significantly brighter *Nanog*:GFP fluorescence (Figure 9A), with FACS analysis showing that the peak of cells expressing maximal *Nanog*:GFP is located at higher fluorescence values for T β C44Cre6 compared with TNG cells (Figure 9B). Therefore, even in '2i + LIF', undifferentiated *Nanog*-null cells transcribe the *Nanog* locus more efficiently than NANOG-expressing cells.

Next, we used 44NERTc3 and 44iN cells to assess the effects of restoring NANOG activity in '2i + LIF' conditions. In both lines, FACS analyses showed that restoration of NANOG with either Tamoxifen (44NERTc3; Figure 9C) or Doxycycline (44iN; Figure 9D) induced a shift of the GFP peak to lower values of fluorescence. However, this did not lead to an increase in the percentage of cells lacking *Nanog*:GFP expression as observed in serum-containing medium (Figure 7). Rather, the proportion of 44NERTc3 and 44iN cells expressing

Figure 9 NANOG-mediated repression of *Nanog* is operational in '2i + LIF'. (A) Representative pictures of TNG and TβC44Cre6 cells cultured in serum-free '2i + LIF' medium. Note the extensive differentiation observed in *Nanog*-null TβC44Cre6. (B) FACS analysis of TNG and TβC44Cre6 cells cultured in serum-free '2i + LIF' medium. (C) FACS analysis of 44NERTc3 cells cultured in serum-free '2i + LIF' medium in the presence or absence of Tamoxifen. (D) Identical analysis of 44iN cells cultured in the presence or absence of Doxycycline. (E) Representative pictures of 44NERTc3 cells cultured in '2i + LIF' in the presence/absence of Tamoxifen. (F) Expression of *Nanog* locus derived pre-mRNA from 44NERTc3 cells grown in parallel in serum (FCS, set to 1), in '2i + LIF' or in '2i + LIF' supplemented with Tamoxifen for 24 h ($n=2$ for each condition, error bars represent s.e.m.). (G) FACS analysis of TNG/T cells cultured in '2i + LIF' and supertransfected with either an empty vector (EV) or a NANOG-expressing vector (NANOG). (H) Model architecture of the core regulatory network of ES cells.

intermediate and low levels of *Nanog*:GFP was decreased upon restoration of NANOG (Figure 9C and D), correlating with the loss of differentiating cells (Figure 9E).

Overall, these results suggest that *Nanog* autorepression persists in '2i + LIF' and is therefore independent of the MEK/GSK3 signalling pathways. Yet, either MEK and/or GSK3 activities are required to allow NANOG to proceed to generate *Nanog*-silent cells. In agreement with this, analysis of pre-mRNA expression from the endogenous *Nanog* locus in 44NERTc3 cells cultured in '2i + LIF' showed that *Nanog* transcription is downregulated by Tamoxifen treatment but only to a level that is higher than that seen in cells cultured in serum without Tamoxifen (Figure 9F).

The fact that *Nanog*-null cells exhibit an increased differentiation propensity in '2i + LIF' was unexpected. This may indicate that *Nanog*-null cells do not respond appropriately to MEK/GSK3 inhibition, opening the possibility that in cells fully responding to signalling inhibition, *Nanog* repression by NANOG could be abolished. However, upon transfection of a NANOG expression vector, supertransfectable TNG cells (TNG/T) show a clear shift of *Nanog*:GFP expression to lower fluorescence values, without generating *Nanog*:GFP-negative cells (Figure 9G). Therefore, the ability of exogenous NANOG to downregulate *Nanog* in *Nanog*-null cells cultured '2i + LIF' is not due to an inappropriate response of *Nanog*-null cells to signalling inhibition. We conclude that *Nanog* autorepression is independent of MEK/GSK3 signalling.

Discussion

The previous view of the core pluripotency network proposed that *Nanog*, *Oct4* and *Sox2* form a self-reinforcing circuit (Jaenisch and Young, 2008) and was inferred from genome-wide analyses (Loh *et al*, 2006; Ivanova *et al*, 2006; Chen *et al*, 2008; Marson *et al*, 2008; Kim *et al*, 2008). Although based on the reasonable assumption that binding of a transcription factor to a regulatory region of an active gene suggests that the transcription factor acts as an activator, experimental evidence supporting the inferred architecture had not been generated. In particular, how endogenous genes respond to the presence/absence of their regulators has yet to be analysed comprehensively. Although attempts have been made (Loh *et al*, 2006; Ivanova *et al*, 2006; Hall *et al*, 2009), the differentiation events arising upon the loss of several pluripotency genes precludes the drawing of clear conclusions regarding whether the observed genetic responses result from direct regulation or from pleiotropic effects. Here, we took advantage of the fact that undifferentiated and pluripotent *Nanog*-null ES cells can be expanded (Chambers *et al*, 2007), to use genetic approaches to unravel the architecture of the *Nanog*-centred network.

While this manuscript was under revision, an independent study used partial knockdown of *Nanog* mRNA and overexpression of NANOG in WT ES cells to propose that *Nanog* is subject to autorepression (Fidalgo *et al*, 2012). In contrast, we have used inducible systems of complete loss- and gain-of-function. In combination, both studies establish that the architecture of the core pluripotency network needs to be re-assessed by replacing *Nanog* autoactivation by autorepression (Figure 9H). Moreover, our study also argues against the generally accepted idea that NANOG activates *Oct4* and *Sox2*: NANOG is not a critical regulator of *Oct4*/*Sox2*

expression (Figure 9H), an observation that is consistent with the fact that *Nanog*-null ES cells are viable whereas *Oct4* and *Sox2* expression need to be maintained within strict limits to prevent differentiation (Niwa *et al*, 2000; Masui *et al*, 2007). Conversely, our results confirm that NANOG transactivates *Klf4* and *Esrrb* (Festuccia *et al*, 2012).

We further show that *Nanog* autorepression does not rely on the modulation of OCT4/SOX2 activity at the *Nanog* locus. Fidalgo *et al* (2012) proposed that *Nanog* autorepression occurs through interaction between NANOG and the transcriptional repressors ZFP281 and NURD. Interestingly, NANOG does not bind at the *Nanog* locus in the absence of ZFP281 (Fidalgo *et al*, 2011), suggesting that NANOG binding to *Nanog* may be indirect. However, we show here that a mutant NANOG protein unable to bind DNA cannot repress *Nanog*-driven transcription. We also show that the previously *in vitro* identified NANOG-binding site at *Nanog* (Wu *et al*, 2006) is not required to achieve NANOG-mediated repression of *Nanog*-driven transcription. Therefore, further studies will be required to understand in detail the molecular basis of *Nanog* autorepression.

At least two consequences of *Nanog* autorepression could be of biological significance. First, it is known that ectopically enforced NANOG expression captures ES cells in a self-renewal state (Chambers *et al*, 2003). Therefore, *Nanog* autorepression may be an important component that restrains NANOG from reaching a level which completely blocks exit from the undifferentiated state. Second, *Nanog* autorepression may influence the dynamic properties of *Nanog* regulation in undifferentiated ES cells. Accordingly, we show here that *Nanog* autorepression is an important regulatory arm of *Nanog* gene expression heterogeneity. The introduction of OCT4/SOX2-independent *Nanog* autorepression and the liberation of *Oct4*/*Sox2* expression from NANOG-mediated control (Figure 9H) afford an unexpected vantage point to study NANOG heterogeneity within OCT4/SOX2-expressing cells.

In accord with other model systems (Balazsi *et al*, 2011), we report here that *Nanog* autorepression influences the dynamic transitions between *Nanog* transcription states. Indeed, the generation of *Nanog*-inactive cells is significantly impaired in *Nanog*-null cells. Conversely, restoring nuclear NANOG expression to *Nanog*-null cells is sufficient to rescue the ability of the network to explore the *Nanog*-inactive state efficiently, in a process reminiscent to the exit of competence of *Bacillus subtilis* (Suel *et al*, 2007). Remarkably, in the presence of exogenous NANOG, *Nanog*-inactive cells fail to re-enter the *Nanog*-active state. Thus, when the production of NANOG is freed from the autorepressed locus, transcriptional switching of *Nanog* is altered, suggesting that *Nanog* autorepression acts as an information processing system.

Interestingly, not all the cells constitutively expressing exogenous NANOG display silent *Nanog* genes and, conversely, not all cells lacking NANOG permanently transcribe *Nanog*, as shown by our RNA-FISH experiments. This suggests that other activities are likely to buffer the efficiency of *Nanog* autorepression in NANOG-overexpressing cells or to restrain full activation of *Nanog* in *Nanog*-null cells. Since genetic networks supporting excitable non-linear dynamics are generally structured in intertwined positive and negative feedback loops (Balazsi *et al*, 2011), it is possible that

secondary effects of gain- or loss-of-function of NANOG counteract those derived from the direct repression of *Nanog* by NANOG. *Oct4* and *Sox2* expression are not under the tight control of NANOG. Therefore, it will be important to determine which pluripotency transcription factors establish such positive feedback modules in the *Nanog*-centred network. Indeed, secondary, NANOG-dependent feedback loops have recently been suggested to contribute to ES cell heterogeneity (Macarthur *et al*, 2012). The NANOG targets *Esrrb* and *Klf4* (Festuccia *et al*, 2012) have been suggested to act as transcriptional activators of *Nanog* (van den Berg *et al*, 2008; Niwa *et al*, 2009). *Esrrb* and *Klf4* are therefore likely to establish positive feedback loops that may explain the fact that *Nanog* is neither homogeneously silent in cells over-expressing NANOG from a transgene, nor homogeneously active in cells lacking NANOG.

As recently reported (Miyanari and Torres-Padilla, 2012), we also found *Nanog* to be largely monoallelically transcribed in ES cells. Although *Nanog* autorepression does not seem to have a critical influence on the proportion of mono- versus biallelically transcribing cells, this does not rule out the possibility that allelic switching contributes to NANOG heterogeneity (Miyanari and Torres-Padilla, 2012). Indeed, the variability in NANOG levels generated through allelic switching, together with the subsequent modulation of the probability for *Nanog* transcription, might be a source of perturbations with potentially important dynamic consequences.

Until now, NANOG heterogeneity had been shown to be exclusively modulated by extrinsic signalling pathways. Indeed, NANOG heterogeneity is abolished in serum-free conditions in which the MEK and GSK3 signalling pathways are inhibited (the so-called '2i + LIF' conditions; Ying *et al*, 2008; Wray *et al*, 2011; Marks *et al*, 2012). Therefore, the fact that the experimental manipulation of NANOG activity leads to drastic alterations of *Nanog* transcription heterogeneity without any artificial manipulation of MEK/GSK3 signalling, places *Nanog* autorepression as a major regulatory arm of NANOG heterogeneity. Thus, at least one intrinsic activity, *Nanog* autorepression, contributes to the existence of reversible phenotypic states associated with distinct propensities for self-renewal or differentiation.

Interestingly in this context, the repression of *Nanog* by exogenous NANOG persists in '2i + LIF', yet without giving rise to *Nanog*-negative cells. This suggests that, although the MEK/GSK3 signalling pathways are not required for *Nanog* autorepression to occur, they do promote the ability of *Nanog* autorepression to generate cells in which *Nanog* is not transcribed. A multitude of transcription factors, including KLF4 and ESRRB, are upregulated in '2i + LIF' (Marks *et al*, 2012), suggesting that the global level of *Nanog* activators might be too high to allow *Nanog* autorepression to generate cells expressing no NANOG. Conversely, the transcriptional repressor TCF3 is not functional in '2i + LIF' (Wray *et al*, 2011), releasing the repression it normally exerts on *Nanog* and on several other components of the pluripotency network. In this regard, the MEK/GSK3 signalling pathways should not be viewed as specific drivers of *Nanog* heterogeneity, but rather as the inducers of a regulatory landscape in which the consequences of *Nanog* autorepression can be fully unfolded to give rise to heterogeneous and fluctuating *Nanog* transcription.

Overall, this study suggests that non-genetic heterogeneity of *Nanog* transcription is an emergent property of the subnetwork architecture proposed here (Figure 9H), which nevertheless depends on the signalling-dependent modulation of the activity of the global pluripotency network. Identifying the transcription factors and upstream signalling molecules that enable *Nanog* autorepression to promote NANOG heterogeneity should provide novel insights into how intrinsic and extrinsic regulations cooperate to control pluripotency.

Materials and methods

Cell culture

Cells were cultured as previously described (Festuccia *et al*, 2012). Tamoxifen (Sigma) and Cycloheximide (Sigma) were used at 1 μ M and 30 μ g/ml, respectively. Doxycycline (Sigma) was used at 1 μ g/ml except when indicated. For the analysis of *Nanog*:GFP heterogeneity, cells were cultured in the presence of the appropriate selection for *Nanog* transcription (Puromycin for TNG ES cells, G418 for T β C44Cre6 and 44NERT ES cells) and then plated at similar density (0.1×10^5 cells per well of a six-well plate) and cultured for 5 days in the absence of selection. After FACS-sorting, 0.1×10^5 cells were plated per well of a six-well plate and cultured in the absence of selection.

Random reverse transcription

RNA was extracted with TRIZOL (Invitrogen), DNase treated (Qiagen) and reverse transcribed with SuperScriptIII (Invitrogen).

Chromatin immunoprecipitation

Chromatin was extracted, sonicated and immunoprecipitated as previously described (Navarro *et al*, 2011).

Quantitative PCR

(Q)PCR reactions were performed in 384-well plates with a 480 LightCycler (Roche) using LightCycler 480 SYBR Green I Master (Roche). All primers were designed after repeat masking; sequences are available as Supplementary Information.

RNA-FISH

The *Nanog* intron 1 probe was generated by PCR (TAKARA Ex Taq) using available vectors carrying the *Nanog* locus genomic DNA (Chambers *et al*, 2007). Probe labelling was performed with the Vysis Nick Translation kit, using Spectrum Red or Green dUTP and following the manufacturer instructions. Cells were cytospun, permeabilised, fixed and hybridised as described (Navarro *et al*, 2008). Visualisation was performed with a Nikon TE-2000 microscope and a CoolSnapHQ High Speed Monochrome CCD or an Evolve 512 EMCCD camera (Photometrics). Image stacks (0.3 μ m steps) were acquired with Metamorph software and deconvolved with AutoQuant.

FACS analysis

Cells were stained with anti-SSEA-1 monoclonal antibody (Clone MC-480, Developmental Studies Hybridoma Bank, The University of Iowa) using Alexa fluor-647 conjugated goat anti-mouse IgM antibodies (Invitrogen, Molecular Probes). *Nanog*:GFP and SSEA-1 expression was quantified using a FACSCalibur or an LSR II flow-cytometer system (Becton, Dickinson). The data was analysed using the FlowJo software suite (Tree Star).

Supplementary data

Supplementary data are available at *The EMBO Journal* Online (<http://www.embojournal.org>).

Acknowledgements

We are grateful to Olivia Rodriguez for technical assistance with FACS sorting, to Carsten Marr and Peter Swain for discussions; to Val Wilson, Claus Nerlov, Philippe Clerc and Phil Avner for critical

reading of the manuscript. PN was supported by a Newton International Fellowship and by a Marie Curie Intra-European Fellowship. Research in I.C.'s laboratory was supported by the Medical Research Council of the UK, The Wellcome Trust and by the EU Framework 7 project 'EuroSyStem' and by a Conacyt studentship (RO).

Author contributions: PN and IC conceived the study and wrote the manuscript. PN also performed and analysed the experiments with inputs from NF. NF generated the NANOG-ER¹² expression vector and characterised and analysed Nanog:GFP expression.

References

- Balazsi G, van Oudenaarden A, Collins JJ (2011) Cellular decision making and biological noise: from microbes to mammals. *Cell* **144**: 910–925
- Chambers I, Colby D, Robertson M, Nichols J, Lee S, Tweedie S, Smith A (2003) Functional expression cloning of Nanog, a pluripotency sustaining factor in embryonic stem cells. *Cell* **113**: 643–655
- Chambers I, Silva J, Colby D, Nichols J, Nijmeijer B, Robertson M, Vrana J, Jones K, Grotewold L, Smith A (2007) Nanog safeguards pluripotency and mediates germline development. *Nature* **450**: 1230–1234
- Chazaud C, Yamanaka Y, Pawson T, Rossant J (2006) Early lineage segregation between epiblast and primitive endoderm in mouse blastocysts through the Grb2-MAPK pathway. *Dev Cell* **10**: 615–624
- Chen X, Xu H, Yuan P, Fang F, Huss M, Vega VB, Wong E, Orlov YL, Zhang W, Jiang J, Loh YH, Yeo HC, Yeo ZX, Narang V, Govindarajan KR, Leong B, Shahab A, Ruan Y, Bourque G, Sung WK et al (2008) Integration of external signaling pathways with the core transcriptional network in embryonic stem cells. *Cell* **133**: 1106–1117
- Dietrich JE, Hiragi T (2007) Stochastic patterning in the mouse pre-implantation embryo. *Development* **134**: 4219–4231
- Festuccia N, Osorno R, Halbritter F, Karwacki-Neisius V, Navarro P, Colby D, Wong F, Yates A, Tomlinson SR, Chambers I (2012) Esrrb is a direct Nanog target gene that can substitute for Nanog function in pluripotent cells. *Cell Stem Cell* **11**: 477–490
- Fidalgo M, Faiola F, Pereira CF, Ding J, Saunders A, Gingold J, Schaniel C, Lemischka IR, Silva JC, Wang J (2012) Zfp281 mediates Nanog autorepression through recruitment of the NuRD complex and inhibits somatic cell reprogramming. *Proc Natl Acad Sci USA* **109**: 16202–16207
- Fidalgo M, Shekar PC, Ang YS, Fujiwara Y, Orkin SH, Wang J (2011) Zfp281 functions as a transcriptional repressor for pluripotency of mouse embryonic stem cells. *Stem Cells* **29**: 1705–1716
- Graf T, Stadtfeld M (2008) Heterogeneity of embryonic and adult stem cells. *Cell Stem Cell* **3**: 480–483
- Hall J, Guo G, Wray J, Eyres I, Nichols J, Grotewold L, Morfopoulou S, Humphreys P, Mansfield W, Walker R, Tomlinson S, Smith A (2009) Oct4 and LIF/Stat3 additively induce Kruppel factors to sustain embryonic stem cell self-renewal. *Cell Stem Cell* **5**: 597–609
- Huang S (2009) Non-genetic heterogeneity of cells in development: more than just noise. *Development* **136**: 3853–3862
- Ivanova N, Dobrin R, Lu R, Kotenko I, Levorse J, DeCoste C, Schafer X, Lun Y, Lemischka IR (2006) Dissecting self-renewal in stem cells with RNA interference. *Nature* **442**: 533–538
- Jaenisch R, Young R (2008) Stem cells, the molecular circuitry of pluripotency and nuclear reprogramming. *Cell* **132**: 567–582
- Kalmar T, Lim C, Hayward P, Munoz-Descalzo S, Nichols J, Garcia-Ojalvo J, Martinez Arias A (2009) Regulated fluctuations in nanog expression mediate cell fate decisions in embryonic stem cells. *PLoS Biol* **7**: e1000149
- Kim J, Chu J, Shen X, Wang J, Orkin SH (2008) An extended transcriptional network for pluripotency of embryonic stem cells. *Cell* **132**: 1049–1061
- Kuroda T, Tada M, Kubota H, Kimura H, Hatano SY, Suemori H, Nakatsuji N, Tada T (2005) Octamer and Sox elements are required for transcriptional cis regulation of Nanog gene expression. *Mol Cell Biol* **25**: 2475–2485
- AG performed the immunoblots. VKN, RO and DC provided technical assistance. NM generated the NANOG:N51A expression vector and WZ the luciferase reporter constructs. DK provided microscopy support. MR generated preliminary evidence for Nanog autorepression.

Conflict of interest

The authors declare that they have no conflict of interest.

- Rodda DJ, Chew JL, Lim LH, Loh YH, Wang B, Ng HH, Robson P (2005) Transcriptional regulation of nanog by OCT4 and SOX2. *J Biol Chem* **280**: 24731–24737
- Silva J, Smith A (2008) Capturing pluripotency. *Cell* **132**: 532–536
- Singh AM, Hamazaki T, Hankowski KE, Terada N (2007) A heterogeneous expression pattern for Nanog in embryonic stem cells. *Stem Cells* **25**: 2534–2542
- Suel GM, Kulkarni RP, Dworkin J, Garcia-Ojalvo J, Elowitz MB (2007) Tunability and noise dependence in differentiation dynamics. *Science* **315**: 1716–1719
- van den Berg DL, Zhang W, Yates A, Engelen E, Takacs K, Bezstarosti K, Demmers J, Chambers I, Poot RA (2008) Estrogen-related receptor beta interacts with Oct4 to positively regulate Nanog gene expression. *Mol Cell Biol* **28**: 5986–5995
- Ying QL, Wray J, Nichols J, Battle-Morera L, Doble B, Woodgett J, Cohen P, Smith A (2008) The ground state of embryonic stem cell self-renewal. *Nature* **453**: 519–523
- Wray J, Kalkan T, Smith A (2010) The ground state of pluripotency. *Biochem Soc Trans* **38**: 1027–1032
- Wray J, Kalkan T, Gomez-Lopez S, Eckardt D, Cook A, Kemler R, Smith A (2011) Inhibition of glycogen synthase kinase-3 alleviates Tcf3 repression of the pluripotency network and increases embryonic stem cell resistance to differentiation. *Nat Cell Biol* **13**: 838–845
- Wu Q, Chen X, Zhang J, Loh YH, Low TY, Zhang W, Zhang W, Sze SK, Lim B, Ng HH (2006) Sall4 interacts with Nanog and co-occupies Nanog genomic sites in embryonic stem cells. *J Biol Chem* **281**: 24090–24094